Sa1903 Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease

Ginard, Daniel; Khorrami, Sam; Marín-Jiménez, Ignacio; Chaparro, María; Aguas, Mariam; Muñoz, Fernándo; Martínez‐González, Javier; Cabriada, José Luis; García–Sánchez, Valle; Villòria, Albert; Casellas, Francesc; Sansó, Andreu; Riera, J. Castella; Hervías, Daniel; Garcia, S.; García, E. Juncadella; Gisbert, Javier P.

doi:10.1016/s0016-5085(12)61338-9

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a double‐blind cross‐over trial, ustekinumab has been shown to be effective in the treatment of moderate‐to‐severe CD . More recent open‐label use has supported this early data …”

Section: Resultsmentioning

confidence: 84%

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Moran

Lim

Bailey

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background With the expanding list of medications available to treat patients with inflammatory bowel disease (IBD), it is important to recognise adverse events, including those involving the skin. Dermatological adverse events may be confused with extra‐intestinal manifestations of IBD. Aim To review drug‐related dermatological manifestations associated with immunosuppressive and anti‐tumour necrosis factor (anti‐TNF) therapy. Methods The literature was searched on PubMed for dermatological adverse events in IBD. Results Present thiopurine exposure was associated with a 5.9‐fold [95% confidence interval (CI), 2.1–16.4] increased risk of developing non‐melanoma skin cancer (NMSC). The peak incidence is highest in Caucasians over the age of 65 years with crude incidence rates of 4.0 and 5.7/1000 patient‐years for present and previous use. In anti‐TNF‐exposed subjects, drug‐induced lupus was reported in 1% of the cases and a psoriatic rash in up to 3% of the cases. Anti‐TNF monotherapy increases the risk of NMSC ~2‐fold to a rate of 0.5 cases per 1000 person‐years. Cutaneous lymphomas have been rarely reported in subjects on thiopurine or anti‐TNF drug monotherapy. Combination therapy seems to have an additive effect on the risk of developing NMSC and lymphoma. Conclusions Physicians need to be aware of the wide spectrum of dermatological complications of immunosuppressive and anti‐TNF therapy in IBD, especially psoriasis and non‐melanoma skin cancer. Vigilance and regular screening for non‐melanoma skin cancer is recommended. Case discussions between gastroenterologists and dermatologists should be undertaken to best manage dermatological adverse events.

show abstract

Section: Resultsmentioning

confidence: 84%

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Moran

Lim

Bailey

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…29 Although the dosing used in psoriasis is typically lower than doses used in CD, very few serious AEs to ustekinumab have been reported in RCTs and open-label cohorts of CD patients. [16][17][18][19] There are several limitations to our study. Primarily, this was a retrospective evaluation.…”

Section: Discussionmentioning

confidence: 97%

“…Safety of ustekinumab has also been well‐evaluated in the psoriasis population; pooled results from 3117 patients treated with ustekinumab for psoriasis found an event rate of 1.19 serious infections per 100‐patient‐years exposure . Although the dosing used in psoriasis is typically lower than doses used in CD, very few serious AEs to ustekinumab have been reported in RCTs and open‐label cohorts of CD patients …”

Section: Discussionmentioning

confidence: 99%

“…Few studies have described the open-label experience with ustekinumab in CD and currently published series are limited by small sample size, lack of objectively defined response, and short duration of follow-up. [16][17][18][19] Here, we aim to describe the real world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in a large multicentre cohort of CD patients failing anti-TNF therapy. Second, we assess predictors of response and the safety profile of ustekinumab.…”

Section: Introductionmentioning

confidence: 99%

“…Gastroenterologists have previously accessed ustekinumab through compassionate release programs or clinical trials. Few studies have described the open‐label experience with ustekinumab in CD and currently published series are limited by small sample size, lack of objectively defined response, and short duration of follow‐up . Here, we aim to describe the real world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in a large multicentre cohort of CD patients failing anti‐TNF therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

Fedorak

Kaplan

et al. 2017

Aliment Pharmacol Ther

155

136

View full text Add to dashboard Cite

show abstract

El futuro de la enfermedad inflamatoria intestinal desde la perspectiva de la DDW 2012

Gomollón

2012

Gastroenterología y Hepatología

View full text Add to dashboard Cite

Sa1903 Effectiveness and Safety of Ustekinumab as Rescue Therapy in Multi-Drug Resistant Crohn's Disease

Cited by 7 publications

References 0 publications

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

El futuro de la enfermedad inflamatoria intestinal desde la perspectiva de la DDW 2012

Contact Info

Product

Resources

About